Considering that the key metabolically disturbed trait of PCOS (defined as insulin resistance) resembles that of diabetes, and there are common accompanying features of the two (including obesity, low grade inflammation, metabolic abnormalities and increased risk of cardiovascular events) (Berni et al., 2021; Wekker et al., 2020), it is reasonable to propose that SGLT2 inhibitors could be beneficial for patients with PCOS, and it is worthwhile exploring any emerging mechanisms that are supplementary except for improving metabolic abnormalities. This evidence concerns the gene SLC5A2 and diabetes mellitus.